Orient Europharma Co (ROCO:4120) ROCE % : -1.69% (As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Orient Europharma Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Orient Europharma Co's annualized ROCE % for the quarter that ended in Mar. 2024 was -1.69%.

Orient Europharma Co ROCE % Historical Data

The historical data trend for Orient Europharma Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orient Europharma Co ROCE % Chart

Orient Europharma Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

7.10

5.01

2.06

-4.04

5.28

Orient Europharma Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															4.81	-10.85	-0.07	26.22	-1.69

Orient Europharma Co ROCE % Calculation

Orient Europharma Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	362.351	/	( ( (10430.304 - 3793.271)	+	(10811.794 - 3712.225) )	/ 2 )
	=	362.351	/	( (6637.033	+	7099.569)	/ 2 )
	=	362.351	/	6868.301
	=	5.28 %

Orient Europharma Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-120.188	/	( ( (10811.794 - 3712.225)	+	(10927.121 - 3821.26) )	/ 2 )
	=	-120.188	/	( ( 7099.569	+	7105.861 )	/ 2 )
	=	-120.188	/	7102.715
	=	-1.69 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Orient Europharma Co (ROCO:4120) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Orient Europharma Co ROCE % Related Terms

Thank you for viewing the detailed overview of Orient Europharma Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Orient Europharma Co (ROCO:4120) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orient Europharma Co Ltd (ROCO:4120) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

13F., No. 128, Chengde Rd., Sec. 6,, Beitou Distrit, Taipei, TWN, 112052

Website

https://www.oep.com.tw

Orient Europharma Co Ltd is a Taiwan-based company engaged in the wholesale of f Western Pharmaceutical and Medical Devices. The firm also Manufacture Drugs and Medicines, Beverages, Cleaning Preparations, Cosmetics, Medical Devices, and Other Food Products. Its products cover various therapeutic areas, including the central nervous system, cardiovascular, diabetes, allergy, cosmetics, and health supplements.

Orient Europharma Co (ROCO:4120) Headlines

No Headlines